Skip to content
DataLookout
Menu

ENDURENCT06270719

An Observational Study Comparing Delandistrogene Moxeparvovec (ELEVIDYS) With Standard of Care in Participants With Duchenne Muscular Dystrophy

StatusEnrolling by Invitation
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 14 versions: 14 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion moved earlier from Dec 31, 2029 to Dec 31, 2028
    • Eligibility criteria expanded, about 13 words
    • Primary endpoints: details revised at 1 of 2 entries
    • Trial sites expanded: 25 → 29 locations
  2. Notable Eligibility criteria expanded, about 54 words
    • Primary endpoints: 1 to 2
    • Secondary endpoints: 8 to 11
    • Study title expanded, about 1 word
    v13
  3. Minor Study sites: 22 to 25v12
  4. Minor Study sites: 19 to 22v11
  5. Minor Trial status: Recruiting to Enrolling by Invitation
    • Study sites: 17 to 19
    v10
Show 8 earlier versionsHide 8 earlier versions
  1. Minor Study sites: 15 to 17v9
  2. Minor Study sites: 13 to 15v8
  3. Notable Eligibility criteria expanded, about 6 wordsv7 Show 4 more changesShow less
    • Primary endpoint revised
    • Study sites: 9 to 13
    • Interventions: Standard of Care (Drug), delandistrogene moxeparvovec (Genetic) to Delandistrogene Moxeparvovec (Genetic), Standard of Care (Drug)
    • Secondary endpoints: 9 to 8
  4. Minor Study sites: 6 to 9v6
  5. Minor Study sites: 5 to 6v5
  6. Minor Study sites: 4 to 5v4
  7. Minor Study sites: 1 to 4v3
  8. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Feb 29, 2024 to Feb 7, 2024
    • Site details revised
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Mean Change From Baseline in Time to Walk/Run 10 Meters (10MWR) (Calculated Velocity) at Month 12
Timeframe: Baseline, Month 12
Number of Participants Experiencing Acute Liver Injury (ALI)
Timeframe: Baseline through Month 12

Secondary (11)

Time to Rise From Floor (Supine to Stand)
Loss of Ambulation (LOA)
Performance of Upper Limb (PUL) Version 2.0 Entry Item A Score or Brooke Upper Extremity Scale Score
Patient-reported Outcomes Measurement Information (PROMIS) Domain Scores of Mobility, Upper Extremity, and Fatigue
Pulmonary Function as Measured by Forced Vital Capacity (FVC)
Show 6 moreShow less
Pulmonary Function as Measured by FVC Percent Predicted (FVC%p)
Cardiac Function, Including Left Ventricular Ejection Fraction (LVEF), as Measured by Echocardiogram (ECHO) or Cardiac MRI (cMRI)
Number of Participants Experiencing Serious ALI and Acute Liver Failure (ALF)
Number of Participants Experiencing Complications Associated with ALI and ALF
Survival Time
Time to First Vertebral Body (Spine) Fracture

Arms and interventions

Cohort 1 (Treated)

Cohort 1: participants prescribed ELEVIDYS in a commercial setting. Cohort 1a (Ambulatory ELEVIDYS Prospectively Treated Cohort): participants prescribed ELEVIDYS by commercially treating physicians with consent no later than 30 days from infusion. All participants will be dosed with ELEVIDYS based on United States prescribing information (USPI). The Post Market Requirement (PMR) Cohort (sub-cohort of 1a) consists of participants with laboratory data as specified in the ELEVIDYS USPI. Cohort 1b (Non-ambulatory ELEVIDYS Prospectively Treated Cohort): non-ambulatory DMD participants prescribed ELEVIDYS commercially and recruited by treating physicians before infusion (enrollment currently closed). Cohort 1c (ELEVIDYS Retrospectively Treated Cohort): participants dosed with ELEVIDYS with complete baseline data within 6 months prior to dosing and complete prospectively collected annual follow-up data after infusion until the time of cohort entry (sponsor approval required for enrollment).

Cohort 2 (Standard of Care)

Cohort 2: ambulatory DMD participants who are at least 4 years of age at baseline, unexposed to DMD gene therapy, and receiving or prescribed chronic glucocorticoids at study entry.

Genetic: Delandistrogene Moxeparvovec

Drugs: Standard of Care

Sites

29 sites in 1 country